Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down syndrome
2021-002613-34Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by University Medical Center Utrecht. Primary endpoint: Primary antibody-based immune response 28 days after second vaccination. Started Jun 2021; status: active.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002613-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002613-34.